BNTX

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company founded in 2008 and headquartered in Mainz, Germany. The company gained global prominence during the COVID-19 pandemic as the developer of the first approved mRNA-based COVID-19 vaccine in partnership with Pfizer. Originally focused on developing immunotherapies for cancer treatment, BioNTech has evolved into a leading mRNA technology platform company with applications spanning oncology, infectious diseases, and rare diseases. The company went public on NASDAQ in October 2019 and has since established itself as a pioneer in mRNA therapeutics with a robust pipeline of over 20 oncology programs and multiple infectious disease vaccine candidates.